Business Wire

Kalray Unveils Coolidge™ at CES 2020

6.1.2020 20:00:00 EET | Business Wire | Press release

Share

Kalray (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced the company will showcase its MPPA-3 aka Coolidge™, its third generation of unique and patented MPPA® (Massively Parallel Processor Array) processor family at CES 2020 in Las Vegas, from January 7 to 10, 2020.

COOLIDGE™ DEMONSTRATED AT CES

Just a few weeks after having received the first samples of Coolidge from manufacturing, Kalray will showcase a complete Artificial Intelligence use case running on Coolidge at CES, including a common demo with NXP, one of the leading semiconductor companies.

Coolidge samples general availability is planned for April.

COOLIDGE UNIQUELY POSITIONED FOR THE BOOMING MARKET OF INTELLIGENT SYSTEMS

Coolidge represents a 25X performance improvement (1) over second generation MPPA, with improvement of artificial intelligence capacities, increased ease of programming and higher-performance interfaces in particular for next generation of data centers.

Coolidge is targeting the booming market of intelligent systems, from next generation of data center infrastructure, 5G to next generation of cars. Coolidge is a compelling choice versus FPGA, which are expensive and difficult to program; GPU, which are tailored for mathematical algorithms; and AI processors, designed for AI only. Coolidge-based cards can be configured to deliver specialized acceleration performance in a wide set of demanding functions such as vision, signal processing, encryption, software stacks, real-time protocols, etc.

Eric Baissus, CEO of Kalray comments: “Yet another important phase for the company. Coolidge is the platform to support company's ambitions on data center markets, answering needs of growing diversity of Data Center workload acceleration and on automotive, enabling integration of multiple critical functions on the same chip while providing huge computing performance.”

DATA CENTER’S GROWING NEED FOR ACCELERATIONS AT COMPUTE, STORAGE AND NETWORKING

“2CRSi is eager to evaluate the new Coolidge processor from Kalray and excited to explore solutions leveraging Kalray’s configurable cards. The performance of this third-generation processor will enable an expansion of our offer in high-growth areas such as Artificial Intelligence or compute acceleration, while enabling more and more distributed and disaggregated data center implementations”, said Alain Wilmouth, CEO of 2CRSi.

AUTOMOTIVE AND EMBEDDED MARKETS NEED FOR INTEGRATION OF MULTIPLE CRITICAL FUNCTIONS AND HIGH COMPUTE PERFORMANCE

“We are very happy to see the strategic partnership with Kalray reach a new milestone and have Coolidge integrated into the NXP BlueBox, our development platform for automated driving, showcased at CES. We are convinced NXP and Kalray will bring multiple benefits to the development and industrialization of ADAS and AD vehicles with safe and secure solutions integrating multiple critical functions and providing very high computing performance” said Kamal Khouri, Vice President & General Manager, Advanced Driver Assistance, NXP.

Coolidge has been designed to address the challenges and constraints of the new generation of intelligent systems:

  • High computing power with low energy consumption
  • Open and easily programmable system
  • Real-Time data processing and deterministic behavior
  • Concurrent execution of many heterogeneous critical tasks in parallel on a single chip
  • Advanced security and safety mechanisms suitable for the most demanding systems, defined in collaboration with Kalray’s partners in the aerospace, defense and automotive fields

For more information and to view the demonstrations, come and visit us at CES from January 7 to 10 at Las Vegas, USA: NXP’s booth #CP18, Central Plaza.

Next publication:

January 22, 2020: H2 2019 business report

ABOUT KALRAY

Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is the pioneer in processors for new intelligent systems. A genuine technological breakthrough, “intelligent” processors are able to intelligently analyze a vast quantity of data on the fly and to make decisions and interact in real time with the outside world. These intelligent processors will be largely deployed in fast-growing sectors such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as in healthcare equipment, drones and robots. Kalray’s offering spans both processors and global solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l’Énergie Atomique”, the French Alternative Energies and Atomic Energy Commission), Kalray addresses a broad spectrum of customers including server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers. Read more at: www.kalrayinc.com

1 25 TOPS (Tera Operations Per Second) performance for Coolidge versus 1 TOPS for previous generation Bostan

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalray.eu
Tel. +33 (0)4 76 18 90 71

ACTUS finance & communication
Caroline LESAGE
kalray@actus.fr
+ 33 1 53 67 36 79

MEDIA CONTACTS
Loic HAMON
communication@kalray.eu
Tel. +33 (0)4 76 18 90 71

ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel. +33 (0)4 72 18 04 92

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye